Cutia Therapeutics (02487) disclosed a Next Day Disclosure Return dated 03 November 2025, reporting an increase in the total number of its issued ordinary shares. The move resulted from the exercise of restricted share units and share options under the company’s Pre-IPO Equity Incentive Plan.

According to the announcement, the number of issued ordinary shares (excluding treasury shares) rose from 348,370,511 to 363,368,277, a total increase of 14,997,766. The company’s treasury share balance of 1,362,600 remained unchanged, bringing the aggregate number of issued shares to 364,730,877 as of 03 November 2025.

The company indicated that the new shares were issued at various exercise prices, including USD 0.00002, USD 0.06, and USD 0.396, depending on the terms of the underlying awards or options. All issuances were duly authorized by the board of directors and complied with applicable listing rules and legal requirements.